BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29483709)

  • 1. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.
    Sidana S; Tandon N; Dispenzieri A; Gertz MA; Dingli D; Jevremovic D; Morice WG; Kapoor P; Kourelis TV; Lacy MQ; Hayman SR; Buadi FK; Leung N; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust SR; Warsame R; Hwa YL; Hobbs M; Fonder A; Kyle RA; Rajkumar SV; Kumar SK; Gonsalves WI
    Leukemia; 2018 Jun; 32(6):1421-1426. PubMed ID: 29483709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
    Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
    Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.
    Muchtar E; Jevremovic D; Dispenzieri A; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Chakraborty R; Zeldenrust S; Kumar SK; Kyle RA; Rajkumar SV; Gertz MA
    Blood; 2017 Jan; 129(1):82-87. PubMed ID: 27729322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
    Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
    Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Blood Cancer J; 2016 Dec; 6(12):e512. PubMed ID: 27983726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.
    Rodríguez-Lobato LG; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Aróstegui JI; Rosiñol L; Díaz T; Lozano E; Yagüe J; Bladé J
    Amyloid; 2017 Dec; 24(4):245-252. PubMed ID: 29052436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
    Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
    Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
    Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
    Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
    Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
    Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
    Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis.
    Sidiqi MH; Aljama MA; Jevremovic D; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz MA
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2360-2364. PubMed ID: 29964192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
    Puig N; Paiva B; Lasa M; Burgos L; Perez JJ; Merino J; Moreno C; Vidriales MB; Toboso DG; Cedena MT; Ocio EM; Lecumberri R; García de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Pérez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Prosper F; Martinez-Lopez J; Lecrevisse Q; Verde J; Mateos MV; Lahuerta JJ; Orfao A; San Miguel JF
    Leukemia; 2019 May; 33(5):1256-1267. PubMed ID: 30542145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.
    Gonsalves WI; Rajkumar SV; Gupta V; Morice WG; Timm MM; Singh PP; Dispenzieri A; Buadi FK; Lacy MQ; Kapoor P; Gertz MA; Kumar SK
    Leukemia; 2014 Oct; 28(10):2060-5. PubMed ID: 24618735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
    Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
    Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.
    Gonsalves WI; Rajkumar SV; Dispenzieri A; Dingli D; Timm MM; Morice WG; Lacy MQ; Buadi FK; Go RS; Leung N; Kapoor P; Hayman SR; Lust JA; Russell SJ; Zeldenrust SR; Hwa L; Kourelis TV; Kyle RA; Gertz MA; Kumar SK
    Leukemia; 2017 Jan; 31(1):130-135. PubMed ID: 27457702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.
    Gonsalves WI; Jevremovic D; Nandakumar B; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Siddiqui MA; Kyle RA; Gertz MA; Rajkumar SV; Kumar SK
    Am J Hematol; 2020 Mar; 95(3):310-315. PubMed ID: 31867775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
    Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
    Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.